Overslaan en naar de inhoud gaan

 Alle verbonden artikelen

The circular RNome of primary breast cancer.

Auteurs : Smid M, Wilting S, Uhr K, Rodriguez-Gonzalez G, de Weerd V, Prager-Van der Smissen W, van der Vlugt-Daane M, van Galen A, Nik-Zainal S, Butler A, Martin S, Davies H, Staaf J, van de Vijver M, Richardson A, Macgrogan G, Salgado R, Van den Eynden G, Purdie C, Thompson A, Caldas C, Span P, Sweep F, Simpson P, Lakhani S, Van Laere S, Desmedt C, Paradiso A, Eyfjord J, Broeks A, Vincent-Solomon A, Futreal A, Knappskog S, King T, Viari A, Børresen-Dale AL, Stunnenberg H, Stratton M, Foekens J, Sieuwerts A, Martens J
Jaar : 2019
Journal : Genome Res

Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma.

Auteurs : Delhaye C, Hendlisz A, Vouche M
Jaar : 2019
Journal : Curr Opin Oncol

Defining synchronous oligometastatic non-small cell lung cancer: a systematic review.

Auteurs : GiajLevra N, Levra MG, Durieux V, Novello S, Besse B, Hasan B, Hendriks LE, Levy A, Dingemans AC, Berghmans T
Jaar : 2019
Journal : J Thorac Oncol

Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis.

Auteurs : Lechien JR, Saussez S, Schindler A, Karkos PD, Hamdan AL, Harmegnies B, De Marrez LG, Finck C, Journe F, Paesmans M, Vaezi MF
Jaar : 2019
Journal : Laryngoscope
Volume : 129
Pagina's : 1174-1187

Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

Auteurs : Martinez Chanza N, Tripathi A, Harshman LC
Jaar : 2019
Journal : Curr Treat Options Oncol
Volume : 20
Pagina's : 44

Selective oestrogen receptor degraders in breast cancer: a review and perspectives.

Auteurs : Gombos A
Jaar : 2019
Journal : Curr Opin Oncol

Reply to the letter Safety of fertility preservation in women with breast cancer"."

Auteurs : Lambertini M, Anserini P, Del Mastro L
Jaar : 2019
Journal : Breast
Volume : 43
Pagina's : 149-150

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

Auteurs : Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP
Jaar : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pagina's : 5

[Lung cancer: Prognosis in intensive care depends mainly on the acute complication].

Auteurs : Gorham J, Ameye L, Paesmans M, Berghmans T, Sculier JP, Meert AP
Jaar : 2019
Journal : Rev Mal Respir

The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes.

Auteurs : Albisinni S, Pretot D, Al Hajj Obeid W, Aoun F, Quackels T, Peltier A, Roumeguère T
Jaar : 2019
Journal : Prog Urol

Mesenchymal stromal cells and natural killer cells: a complex story of love and hate.

Auteurs : Najar M, Fayyad-Kazan M, Merimi M, Burny A, Bron D, Fayyad-Kazan H, Meuleman N, Lagneaux L
Jaar : 2019
Journal : Curr Stem Cell Res Ther
Volume : 14(1)
Pagina's : 14-21

Unilateral Adrenalectomy Could Be a Valid Option for Primary Nodular Adrenal Disease: Evidence From Twins.

Auteurs : Kyrilli A, Lytrivi M, Bouquegneau MS, Demetter P, Lucidi V, Garcia C, Moreno-Reyes R, Tabarin A, Corvilain B, Driessens N
Jaar : 2019
Journal : J Endocr Soc
Volume : 3
Pagina's : 129-134

Heterogeneity of 68Ga-PSMA PET/CT Uptake in Fibrous Dysplasia.

Auteurs : Plouznikoff N, Garcia C, Artigas C, Entezari K, Flamen P
Jaar : 2019
Journal : Clin Nucl Med

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.

Auteurs : Springuel L, Lonez C, Alexandre B, van Cutsem E, Machiels JH, Van den Eynde M, Prenen H, Hendlisz A, Shaza L, Carrasco J, Canon JL, Opyrchal M, Odunsi K, Rottey S, Gilham DE, Flament A, Lehmann FF
Jaar : 2019
Journal : BioDrugs

Reply to V. Turan et al.

Auteurs : Lambertini M, Partridge AH, Del Mastro L
Jaar : 2019
Journal : J Clin Oncol
Volume : 37
Pagina's : 86-88

Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients.

Auteurs : Chi VLD, Garaud S, De Silva P, Thibaud V, Stamatopoulos B, Berehad M, Gu-Trantien C, Krayem M, Duvillier H, Lodewyckx JN, Willard-Gallo K, Sibille C, Bron D
Jaar : 2019
Journal : BMC Cancer
Volume : 19
Pagina's : 81

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.

Auteurs : Bonnefoi H, Macgrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia JP, Picquenot JM, Thomas J, Tille JC, Slaets L, Bodmer A, Bergh J, Cameron D
Jaar : 2019
Journal : Br J Cancer

FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.

Auteurs : De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, Gu-Trantien C, Migliori E, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Jaar : 2019
Journal : EBioMedicine
Volume : 39
Pagina's : 226-238

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

Auteurs : McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart-Gebhart M, Gradishar WJ, Chia S, Di Leo A, Malorni L
Jaar : 2019
Journal : Eur J Cancer
Volume : 114
Pagina's : 55-66

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

Auteurs : Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber Rd, Piccart-Gebhart M, Di Cosimo S
Jaar : 2019
Journal : Eur J Cancer
Volume : 118
Pagina's : 169-177

Volg ons!

Het onderzoek steunen

Het onderzoek steunen

Het onderzoek aan het Jules Bordet Instituut is afhankelijk van uw gulheid. Doe een gift en neem deel aan de strijd tegen kanker

Meer informatie